104 related articles for article (PubMed ID: 10963203)
1. Expression analysis of classic and non-classic HLA molecules before interferon alfa-2b treatment of melanoma.
Wagner SN; Rebmann V; Willers CP; Grosse-Wilde H; Goos M
Lancet; 2000 Jul; 356(9225):220-1. PubMed ID: 10963203
[TBL] [Abstract][Full Text] [Related]
2. Soluble human leukocyte antigen--G serum level is elevated in melanoma patients and is further increased by interferon-alpha immunotherapy.
Ugurel S; Rebmann V; Ferrone S; Tilgen W; Grosse-Wilde H; Reinhold U
Cancer; 2001 Jul; 92(2):369-76. PubMed ID: 11466692
[TBL] [Abstract][Full Text] [Related]
3. The adjuvant treatment of malignant melanoma.
Reintgen D; Kirkwood J
J Fla Med Assoc; 1997 Mar; 84(3):147-52. PubMed ID: 9143164
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant high-dose interferon alfa-2b in patients with high-risk melanoma.
Jonasch E; Kumar UN; Linette GP; Hodi FS; Soiffer RJ; Ryan BF; Sober AJ; Mihm MC; Tsao H; Langley RG; Cosimi BA; Gadd MA; Tanabe KK; Souba W; Haynes HA; Barnhill R; Osteen R; Haluska FG
Cancer J; 2000; 6(3):139-45. PubMed ID: 10882328
[TBL] [Abstract][Full Text] [Related]
5. Update on the role of adjuvant interferon for high risk melanoma.
Agarwala SS; Kirkwood JM
Forum (Genova); 2000; 10(3):230-9. PubMed ID: 11007931
[TBL] [Abstract][Full Text] [Related]
6. Immunomodulatory effects of high-dose and low-dose interferon alpha2b in patients with high-risk resected melanoma: the E2690 laboratory corollary of intergroup adjuvant trial E1690.
Kirkwood JM; Richards T; Zarour HM; Sosman J; Ernstoff M; Whiteside TL; Ibrahim J; Blum R; Wieand S; Mascari R
Cancer; 2002 Sep; 95(5):1101-12. PubMed ID: 12209697
[TBL] [Abstract][Full Text] [Related]
7. High-dose adjuvant interferon therapy for melanoma.
Licata AG
Dermatol Nurs; 1998 Oct; 10(5):334-6. PubMed ID: 9873271
[TBL] [Abstract][Full Text] [Related]
8. [Interferon for adjuvant therapy in melanoma; although approved, not indicated].
Groenewegen G; Osanto S; van der Rhee HJ; Punt CJ
Ned Tijdschr Geneeskd; 2000 Nov; 144(45):2160-2. PubMed ID: 11086492
[TBL] [Abstract][Full Text] [Related]
9. Dose-dependent treatment benefit in high-risk melanoma patients receiving adjuvant high-dose interferon alfa-2b.
Fluck M; Kamanabrou D; Lippold A; Reitz M; Atzpodien J
Cancer Biother Radiopharm; 2005 Jun; 20(3):280-9. PubMed ID: 15989473
[TBL] [Abstract][Full Text] [Related]
10. Lymphatic mapping and sentinel node biopsy in patients with malignant melanoma.
Reintgen D; Rapaport D; Tanabe KK; Ross M
J Fla Med Assoc; 1997 Mar; 84(3):188-93. PubMed ID: 9143171
[TBL] [Abstract][Full Text] [Related]
11. Malignant melanoma and adjuvant alpha interferon-2b for patients at high risk of relapse.
Gale DM; Kiley KE
Clin J Oncol Nurs; 1998 Jan; 2(1):5-10. PubMed ID: 9481250
[TBL] [Abstract][Full Text] [Related]
12. High density oligonucleotide array analysis of interferon- alpha2a sensitivity and transcriptional response in melanoma cells.
Certa U; Seiler M; Padovan E; Spagnoli GC
Br J Cancer; 2001 Jul; 85(1):107-14. PubMed ID: 11437411
[TBL] [Abstract][Full Text] [Related]
13. Ulceration as a predictive marker for response to adjuvant interferon therapy in melanoma.
McMasters KM; Edwards MJ; Ross MI; Reintgen DS; Martin RC; Urist MM; Noyes RD; Sussman JJ; Stromberg AJ; Scoggins CR
Ann Surg; 2010 Sep; 252(3):460-5; discussion 465-6. PubMed ID: 20739846
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.
Hancock BW; Wheatley K; Harris S; Ives N; Harrison G; Horsman JM; Middleton MR; Thatcher N; Lorigan PC; Marsden JR; Burrows L; Gore M
J Clin Oncol; 2004 Jan; 22(1):53-61. PubMed ID: 14665609
[TBL] [Abstract][Full Text] [Related]
15. Patient management strategies for interferon alfa-2b as adjuvant therapy of high-risk melanoma.
Donnelly S
Oncol Nurs Forum; 1998 Jun; 25(5):921-7. PubMed ID: 9644709
[TBL] [Abstract][Full Text] [Related]
16. Toxicity and feasibility of adjuvant high-dose interferon alpha-2b in patients with melanoma in clinical oncologic practice.
Ravaud A; Bedane C; Geoffrois L; Lesimple T; Delaunay M
Br J Cancer; 1999 Aug; 80(11):1767-9. PubMed ID: 10468294
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant therapy with high-dose interferon alpha 2b in patients with high-risk stage IIB/III melanoma.
Kirkwood JM; Tarhini AA; Moschos SJ; Panelli MC
Nat Clin Pract Oncol; 2008 Jan; 5(1):2-3. PubMed ID: 18030300
[No Abstract] [Full Text] [Related]
18. Adjuvant high-dose interferon revisited.
Sondak VK; Flaherty LE
Cancer J; 2000; 6(3):132-4. PubMed ID: 10882326
[No Abstract] [Full Text] [Related]
19. Who benefits most from adjuvant interferon treatment for melanoma?
Gogas H; Abali H; Ascierto PA; Demidov L; Pehamberger H; Robert C; Schachter J; Eggermont AM; Hauschild A; Espinosa E
Am J Ther; 2015; 22(1):54-60. PubMed ID: 24176884
[TBL] [Abstract][Full Text] [Related]
20. HLA-G in melanoma: A new strategy to escape from immunosurveillance?
Ugurel S; Reinhold U; Tilgen W
Onkologie; 2002 Apr; 25(2):129-34. PubMed ID: 12006763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
